Loading...

Cyclopharm

ASX:CYC
Snowflake Description

Flawless balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CYC
ASX
A$82M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

Cyclopharm Limited engages in the research and development, manufacture, and sale of medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. The last earnings update was 28 days ago. More info.


Add to Portfolio Compare Print
CYC Share Price and Events
7 Day Returns
5.6%
ASX:CYC
2.3%
AU Medical Equipment
1.8%
AU Market
1 Year Returns
14.4%
ASX:CYC
-1.1%
AU Medical Equipment
6%
AU Market
CYC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cyclopharm (CYC) 5.6% 12.8% -2% 14.4% 93% 488.1%
AU Medical Equipment 2.3% 4% -0.1% -1.1% 44.3% 109.3%
AU Market 1.8% 3.9% 7.8% 6% 20.5% 8.4%
1 Year Return vs Industry and Market
  • CYC outperformed the Medical Equipment industry which returned -1.1% over the past year.
  • CYC outperformed the Market in Australia which returned 6% over the past year.
Price Volatility
CYC
Industry
5yr Volatility vs Market

CYC Value

 Is Cyclopharm undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Cyclopharm to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Cyclopharm.

ASX:CYC Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year AU Government Bond Rate 2.3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ASX:CYC
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year AU Govt Bond Rate 2.3%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.93
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.933 (1 + (1- 30%) (0.15%))
0.956
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.96
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.31% + (0.956 * 5.96%)
8.01%

Discounted Cash Flow Calculation for ASX:CYC using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Cyclopharm is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

ASX:CYC DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (AUD, Millions) Source Present Value
Discounted (@ 8.01%)
2019 0.60 Analyst x2 0.56
2020 1.70 Analyst x2 1.46
2021 0.95 Analyst x2 0.75
2022 0.58 Est @ -38.96% 0.43
2023 0.43 Est @ -26.58% 0.29
2024 0.35 Est @ -17.91% 0.22
2025 0.31 Est @ -11.84% 0.18
2026 0.28 Est @ -7.6% 0.15
2027 0.27 Est @ -4.62% 0.14
2028 0.26 Est @ -2.54% 0.12
Present value of next 10 years cash flows A$4.29
ASX:CYC DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= A$0.26 × (1 + 2.31%) ÷ (8.01% – 2.31%)
A$4.75
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= A$4.75 ÷ (1 + 8.01%)10
A$2.20
ASX:CYC Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= A$4.29 + A$2.20
A$6.50
Equity Value per Share
(AUD)
= Total value / Shares Outstanding
= A$6.50 / 68.70
A$0.09
ASX:CYC Discount to Share Price
Calculation Result
Value per share (AUD) From above. A$0.09
Current discount Discount to share price of A$1.24
= -1 x (A$1.24 - A$0.09) / A$0.09
-1206.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Cyclopharm is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cyclopharm's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cyclopharm's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:CYC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$0.00
ASX:CYC Share Price ** ASX (2019-04-26) in AUD A$1.24
Australia Medical Equipment Industry PE Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 34.76x
Australia Market PE Ratio Median Figure of 543 Publicly-Listed Companies 16.33x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cyclopharm.

ASX:CYC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:CYC Share Price ÷ EPS (both in AUD)

= 1.24 ÷ 0.00

-2370.44x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cyclopharm is loss making, we can't compare its value to the AU Medical Equipment industry average.
  • Cyclopharm is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Cyclopharm's expected growth come at a high price?
Raw Data
ASX:CYC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2370.44x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
82.8%per year
Oceania Medical Equipment Industry PEG Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 2.67x
Australia Market PEG Ratio Median Figure of 359 Publicly-Listed Companies 1.39x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cyclopharm, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cyclopharm's assets?
Raw Data
ASX:CYC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.25
ASX:CYC Share Price * ASX (2019-04-26) in AUD A$1.24
Australia Medical Equipment Industry PB Ratio Median Figure of 30 Publicly-Listed Medical Equipment Companies 2.77x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.67x
ASX:CYC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:CYC Share Price ÷ Book Value per Share (both in AUD)

= 1.24 ÷ 0.25

4.99x

* Primary Listing of Cyclopharm.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cyclopharm is overvalued based on assets compared to the AU Medical Equipment industry average.
X
Value checks
We assess Cyclopharm's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Cyclopharm has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CYC Future Performance

 How is Cyclopharm expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
82.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cyclopharm expected to grow at an attractive rate?
  • Cyclopharm's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
  • Cyclopharm's earnings growth is expected to exceed the Australia market average.
  • Cyclopharm's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:CYC Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:CYC Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 82.8%
ASX:CYC Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 11.4%
Australia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13.1%
Australia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.8%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:CYC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:CYC Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 20 2 3 2
2020-12-31 16 3 2 2
2019-12-31 14 1 0 2
ASX:CYC Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 16 -1 0
2018-09-30 16 -1 0
2018-06-30 16 0 -1
2018-03-31 16 0 -1
2017-12-31 16 -1 -2
2017-09-30 15 0 -1
2017-06-30 14 0 -1
2017-03-31 15 0 0
2016-12-31 15 1 1
2016-09-30 14 2 3
2016-06-30 14 4 5
2016-03-31 13 4 5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Cyclopharm's earnings are expected to grow significantly at over 20% yearly.
  • Cyclopharm's revenue is expected to grow by 11.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:CYC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Cyclopharm Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:CYC Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 0.05 0.07 0.03 2.00
2020-12-31 0.03 0.03 0.03 1.00
2019-12-31 0.01 0.01 0.01 1.00
ASX:CYC Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 0.00
2018-09-30 -0.01
2018-06-30 -0.01
2018-03-31 -0.02
2017-12-31 -0.02
2017-09-30 -0.02
2017-06-30 -0.01
2017-03-31 0.00
2016-12-31 0.02
2016-09-30 0.05
2016-06-30 0.09
2016-03-31 0.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Cyclopharm is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Cyclopharm's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cyclopharm has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CYC Past Performance

  How has Cyclopharm performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cyclopharm's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cyclopharm does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Cyclopharm's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cyclopharm's 1-year growth to the AU Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Cyclopharm's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cyclopharm Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:CYC Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 15.53 -0.04 9.25 3.22
2018-09-30 15.70 -0.41 9.13 2.97
2018-06-30 15.86 -0.78 8.99 2.72
2018-03-31 15.72 -1.15 8.84 2.79
2017-12-31 15.58 -1.52 8.73 2.87
2017-09-30 15.03 -1.17 8.35 2.64
2017-06-30 14.48 -0.82 7.96 2.41
2017-03-31 14.68 0.04 7.77 1.78
2016-12-31 14.88 0.89 7.58 1.16
2016-09-30 14.42 2.89 7.29 1.07
2016-06-30 13.96 4.90 6.99 0.99
2016-03-31 13.27 4.85 6.73 0.86
2015-12-31 12.58 4.79 6.46 0.73
2015-09-30 11.58 4.06 6.41 0.69
2015-06-30 10.57 3.32 6.35 0.66
2015-03-31 11.31 3.69 6.60 0.57
2014-12-31 12.05 4.07 6.85 0.49
2014-09-30 12.86 -2.00 7.25 0.26
2014-06-30 13.67 -8.07 7.64 0.03
2014-03-31 12.77 -9.09 7.71 0.03
2013-12-31 11.88 -10.12 7.78 0.04
2013-09-30 11.64 -5.51 7.47 0.04
2013-06-30 11.39 -0.90 7.16 0.03
2013-03-31 11.07 -0.97 6.88 0.03
2012-12-31 10.74 -1.04 6.60 0.02
2012-09-30 10.78 -0.87 6.46 0.02
2012-06-30 10.82 -0.70 6.31 0.03

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cyclopharm has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cyclopharm has efficiently used its assets last year compared to the AU Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cyclopharm improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cyclopharm's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cyclopharm has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CYC Health

 How is Cyclopharm's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cyclopharm's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cyclopharm is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cyclopharm's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cyclopharm's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 128.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cyclopharm Company Filings, last reported 3 months ago.

ASX:CYC Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 17.02 0.12 5.85
2018-09-30 17.02 0.12 5.85
2018-06-30 16.26 0.15 7.61
2018-03-31 16.26 0.15 7.61
2017-12-31 17.25 0.17 8.69
2017-09-30 17.25 0.17 8.69
2017-06-30 17.41 0.00 10.62
2017-03-31 17.41 0.00 10.62
2016-12-31 12.46 0.00 4.59
2016-09-30 12.46 0.00 4.59
2016-06-30 12.32 0.00 6.82
2016-03-31 12.32 0.00 6.82
2015-12-31 13.10 0.20 6.44
2015-09-30 13.10 0.20 6.44
2015-06-30 7.71 0.21 3.61
2015-03-31 7.71 0.21 3.61
2014-12-31 7.76 0.25 3.27
2014-09-30 7.76 0.25 3.27
2014-06-30 3.91 1.51 1.35
2014-03-31 3.91 1.51 1.35
2013-12-31 3.66 2.42 1.22
2013-09-30 3.66 2.42 1.22
2013-06-30 14.83 3.02 1.20
2013-03-31 14.83 3.02 1.20
2012-12-31 15.61 3.62 2.35
2012-09-30 15.61 3.62 2.35
2012-06-30 13.26 4.22 1.94
  • Cyclopharm's level of debt (0.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (65.7% vs 0.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Cyclopharm has sufficient cash runway for more than 3 years based on current free cash flow.
  • Cyclopharm has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 89.7% each year.
X
Financial health checks
We assess Cyclopharm's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cyclopharm has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CYC Dividends

 What is Cyclopharm's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.81%
Current annual income from Cyclopharm dividends. Estimated to be 1.17% next year.
If you bought A$2,000 of Cyclopharm shares you are expected to receive A$16 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Cyclopharm's pays a lower dividend yield than the bottom 25% of dividend payers in Australia (2.5%).
  • Cyclopharm's dividend is below the markets top 25% of dividend payers in Australia (5.71%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:CYC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Oceania Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.7%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.3%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:CYC Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 0.02 2.00
2020-12-31 0.01 2.00
2019-12-31 0.01 2.00
ASX:CYC Past Annualized Dividends Data
Date (Data in A$) Dividend per share (annual) Avg. Yield (%)
2019-02-27 0.010 0.851
2018-08-23 0.010 0.959
2018-02-27 0.010 1.003
2017-08-30 0.010 1.130
2017-02-22 0.010 1.192
2016-08-19 0.010 0.972
2016-02-24 0.010 1.256
2015-08-26 0.010 1.887

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cyclopharm is not paying a notable dividend for Australia, therefore no need to check if the payments are stable.
  • Cyclopharm is not paying a notable dividend for Australia, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Cyclopharm's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Cyclopharm's dividends as it is not paying a notable one for Australia.
Future Payout to shareholders
  • No need to calculate the sustainability of Cyclopharm's dividends in 3 years as they are not expected to pay a notable one for Australia.
X
Income/ dividend checks
We assess Cyclopharm's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cyclopharm afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cyclopharm has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CYC Management

 What is the CEO of Cyclopharm's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
James McBrayer
COMPENSATION A$425,542
AGE 53
TENURE AS CEO 10.8 years
CEO Bio

Mr. James S. McBrayer,, BSPharm, GDM, FAICD, AIM, has been the Managing Director at Cyclopharm Ltd. since June 3, 2008 and also serves as its Chief Executive Officer. Mr. McBrayer has been Company Secretary of Cyclopharm Ltd. since March 25, 2011. He has been the Chief Operating Officer at Lipa Pharmaceuticals Ltd. since January 10, 2005. Mr. McBrayer served as Chief Executive Officer of Lipa Pharmaceuticals Ltd., from October 16, 2006 to August 13, 2007 and served as its Managing Director. Mr. McBrayer served as Managing Director of Australasian Operations for Syncor International (now part of Cardinal Health), and a Director of market development for Cleanaway. He was responsible for establishing Syncor International's operations as well as introducing the concept of radiopharmaceutical outsourcing to the Nuclear Medicine community. Mr. McBrayer has more than 20 years experience in nuclear medicine and is a trained Nuclear Pharmacist. Mr. McBrayer held senior positions in Australia and the USA across various industries including the Managing Director for Syncor in Australia and New Zealand. Mr. McBrayer has been a Director of Cyclopharm Ltd. since June 2008. He is a Fellow of the Australian Institute of Company Directors. He holds a Bachelor of Science in Pharmacy and has completed postgraduate studies in Radiation Biophysics. He has also completed a Graduate Diploma in Management through the Australian Graduate School of management.

CEO Compensation
  • James's compensation has increased whilst company is loss making.
  • James's remuneration is about average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the Cyclopharm management team in years:

8.1
Average Tenure
  • The average tenure for the Cyclopharm management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

James McBrayer

TITLE
CEO, MD
COMPENSATION
A$426K
AGE
53
TENURE
10.8 yrs

Mathew Farag

TITLE
Chief Operating Officer
COMPENSATION
A$333K
TENURE
2.3 yrs

Graham Phillips

TITLE
Finance Manager
COMPENSATION
A$153K

Caryn Cheah

TITLE
Financial Controller
COMPENSATION
A$64K
AGE
48
TENURE
8.1 yrs

Lynn McLauchlin

TITLE
General Manager of Canada
COMPENSATION
A$173K

Bjorn Altmann

TITLE
General Manager of Europe
COMPENSATION
A$157K

Gary Somerville

TITLE
Quality & Regulatory Manager
COMPENSATION
A$152K

Charles Buttigieg

TITLE
Sales & Marketing Manager - Australia
COMPENSATION
A$207K
Board of Directors Tenure

Average tenure and age of the Cyclopharm board of directors in years:

6.4
Average Tenure
70
Average Age
  • The tenure for the Cyclopharm board of directors is about average.
Board of Directors

David Heaney

TITLE
Independent Non-Executive Chairman
COMPENSATION
A$71K
AGE
74
TENURE
2 yrs

James McBrayer

TITLE
CEO, MD
COMPENSATION
A$426K
AGE
53
TENURE
10.8 yrs

Tom McDonald

TITLE
Independent Non-Executive Director
COMPENSATION
A$51K
TENURE
2 yrs

Vanda Gould

TITLE
Non-Executive Director
COMPENSATION
A$51K
AGE
70
TENURE
13.4 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Cyclopharm insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
03. Apr 19 Buy Vanda Gould Individual 28. Feb 19 07. Mar 19 19,412 A$1.25 A$24,340
17. Sep 18 Buy Vanda Gould Individual 10. Sep 18 11. Sep 18 300,000 A$0.90 A$270,000
12. Sep 18 Buy Vanda Gould Individual 03. Sep 18 03. Sep 18 10,000 A$0.90 A$9,000
13. Aug 18 Sell CVC Limited Company 08. Aug 18 08. Aug 18 -1,000,000 A$0.90 A$-898,154
13. Aug 18 Buy CVC Limited Company 29. Jun 18 04. Jul 18 5,000 A$1.01 A$5,039
10. Aug 18 Buy Australian Ethical Investment Ltd Company 08. Aug 18 08. Aug 18 1,000,000 A$0.90 A$901,979
27. Jun 18 Buy James McBrayer Individual 27. Jun 18 27. Jun 18 1,000 A$1.00 A$1,000
26. Jun 18 Buy James McBrayer Individual 22. Jun 18 22. Jun 18 3,225 A$1.01 A$3,269
14. Jun 18 Sell CVC Limited Company 08. Jun 18 08. Jun 18 -2,000,000 A$0.99 A$-1,989,750
14. Jun 18 Buy CVC Limited Company 17. Apr 18 13. Jun 18 667,336 A$1.03 A$672,445
12. Jun 18 Buy Australian Ethical Investment Ltd Company 05. Oct 17 08. Jun 18 2,017,432 A$1.00 A$2,018,603
X
Management checks
We assess Cyclopharm's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cyclopharm has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CYC News

Simply Wall St News

Are Insiders Buying Cyclopharm Limited (ASX:CYC) Stock?

We often see insiders buying up shares in companies that perform well over the long term. … So we'll take a look at whether insiders have been buying or selling shares in Cyclopharm Limited (ASX:CYC). … But logic dictates you should pay some attention to whether insiders are buying or selling shares.

Simply Wall St -

Should You Be Pleased About The CEO Pay At Cyclopharm Limited's (ASX:CYC)

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does James McBrayer's Compensation Compare With Similar Sized Companies. … According to our data, Cyclopharm Limited has a market capitalization of AU$89m, and pays its CEO total annual compensation worth AU$421k.

Simply Wall St -

What Percentage Of Cyclopharm Limited (ASX:CYC) Shares Do Insiders Own?

The big shareholder groups in Cyclopharm Limited (ASX:CYC) have power over the company. … Cyclopharm is a smaller company with a market capitalization of AU$82m, so it may still be flying under the radar of many institutional investors. … Taking a look at the our data on the ownership groups (below), it's seems that.

Simply Wall St -

Have Insiders Been Buying Cyclopharm Limited (ASX:CYC) Shares This Year?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … So before you buy or sell Cyclopharm Limited (ASX:CYC), you may well want to know whether insiders have been buying or selling. … But logic dictates you should pay some attention to whether insiders are buying or selling shares.

Simply Wall St -

Understanding Your Return On Investment In Cyclopharm Limited (ASX:CYC)

and want to better understand how you can grow your money by investing in Cyclopharm Limited (ASX:CYC). … This share represents a portion of capital used by the company to operate the business, and it is important the company is able to use the capital base efficiently to create adequate cash flows for you as an investor. … Thus, to understand how your money can grow by investing in Cyclopharm, you need to look at what the company returns to owners for the use of their capital, which can be done in many ways but today we will use return on capital employed (ROCE)

Simply Wall St -

What Did Cyclopharm Limited's (ASX:CYC) CEO Take Home Last Year?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does James McBrayer's Compensation Compare With Similar Sized Companies. … We took a group of companies with market capitalizations below AU$282m, and calculated the median CEO compensation to be AU$359k

Simply Wall St -

Cyclopharm Limited (ASX:CYC)'s Return on Capital

This is because the actual cash flow generated by the business dictates the potential for income (dividends) and capital appreciation (price increases), which are the two ways to achieve positive returns when buying a stock. … Therefore, looking at how efficiently Cyclopharm is able to use capital to create earnings will help us understand your potential return. … Investors use many different metrics but the analysis below focuses on return on capital employed (ROCE).

Simply Wall St -

Bullish Cyclopharm Limited (ASX:CYC) Insiders Ramp Up Investment In Stock

Cyclopharm Limited engages in the research and development, manufacture, and sale of medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. … A well-known argument is that insiders investing more in their own companies’ shares sends an optimistic signal … A research published in The MIT Press (1998) concluded that stocks following insider buying outperformed the market by 4.5%.

Simply Wall St -

Is It The Right Time To Buy Cyclopharm Limited (ASX:CYC)?

This high level of volatility gives investors the opportunity to enter into the stock, and potentially buy at an artificially low price? … A question to answer is whether Cyclopharm's current trading price of A$1 reflective of the actual value of the? … Let’s take a look at Cyclopharm’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change?

Simply Wall St -

What Investors Should Know About Cyclopharm Limited's (ASX:CYC) Financial Strength

Moving onto cash from operations, its small level of operating cash flow means calculating cash-to-debt wouldn't be too useful, though these low levels of cash means that operational efficiency is worth a look. … For this article’s sake, I won’t be looking at this today, but you can take a look at some of CYC’s operating efficiency ratios such as ROA here. … This indicates room for improvement as its cash flow covers less than a quarter of its borrowings, which means its operating efficiency could be better.

Simply Wall St -

CYC Company Info

Description

Cyclopharm Limited engages in the research and development, manufacture, and sale of medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The company offers diagnostic equipment and consumables, which are used by physicians in the detection of pulmonary embolism. It also provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases; and Ultralute, a patented nuclear medicine technology for use in Mollybdenum-99 generators. The company serves nuclear medicine departments in hospitals and clinics. Cyclopharm Limited is headquartered in Kingsgrove, Australia.

Details
Name: Cyclopharm Limited
CYC
Exchange: ASX
Founded:
A$82,438,647
68,698,873
Website: http://www.cyclopharm.com.au
Address: Cyclopharm Limited
1 The Crescent,
Unit 4,
Kingsgrove,
New South Wales, 2208,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX CYC Ordinary Shares Australian Securities Exchange AU AUD 18. Jan 2007
CHIA CYC Ordinary Shares Chi-X Australia AU AUD 18. Jan 2007
Number of employees
Current staff
Staff numbers
32
Cyclopharm employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/26 10:33
End of day share price update: 2019/04/26 00:00
Last estimates confirmation: 2019/03/01
Last earnings filing: 2019/03/29
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.